- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | Aktionäre von Cardio Diagnostics billigen Direktorenriege und Kapitalmaßnahmen | 1 | Investing.com Deutsch | ||
| 15.10. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.09. | Henkel befördert Frank Tenbrock zum CDIO | 33 | CIO | ||
| 14.08. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 22.07. | Cardio Diagnostics: Medicare gibt vorläufige Erstattungssätze für Herztests bekannt | 1 | Investing.com Deutsch | ||
| 22.07. | Medicare sets preliminary payment rates for Cardio Diagnostics tests | 1 | Investing.com | ||
| CARDIO DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 08.07. | Studienkooperation mit AGEPHA Pharma treibt Aktie von Cardio Diagnostics an | - | Investing.com Deutsch | ||
| 18.06. | Medicover AB: Lukasz Krause new Chief Digital Information Officer (CDIO) Medicover | 273 | GlobeNewswire (Europe) | Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover.
Lukasz brings a wealth of experience in IT management having successfully overseen... ► Artikel lesen | |
| 10.06. | Cardio Diagnostics secures Japan patent for heart disease biomarkers | 1 | Investing.com | ||
| 10.06. | Cardio Diagnostics sichert sich japanisches Patent für Herzerkrankungsbiomarker | - | Investing.com Deutsch | ||
| 09.06. | Cardio Diagnostics Holdings, Inc. (CDIO): A Bull Case Theory | 1 | Insider Monkey | ||
| 29.05. | Cardio Diagnostics Regains Nasdaq Compliance After Reverse Stock Split | 1 | RTTNews | ||
| 29.05. | Cardio Diagnostics regains Nasdaq compliance following reverse stock split | 2 | Seeking Alpha | ||
| 28.05. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05. | Cardio Diagnostics announces 1-for-30 reverse stock split | 2 | Seeking Alpha | ||
| 08.05. | Cardio Diagnostics enacts 1-for-30 reverse stock split | 1 | Investing.com | ||
| 08.05. | Cardio Diagnostics drops on 1-for-30 reverse stock split | 1 | Seeking Alpha | ||
| 08.05. | Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split | 996 | Business Wire | CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. ("Cardio" or the "Company") (NASDAQ: CDIO), today announced a 1-for-30 reverse stock split of its common stock effective with the market opening... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 6,972 | +1,54 % | Rheinmetall: Ziel 1.500 Euro? - BYD, Circus, Evotec, Novo Nordisk und stock3 im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,170 | -0,52 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,900 | -2,21 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| NURIX THERAPEUTICS | 11,090 | +6,63 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 5,805 | -11,91 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,900 | +1,80 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| 89BIO | 14,785 | -0,10 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,340 | +13,40 % | 4D Molecular Therapeutics stock maintains Outperform rating at RBC Capital |
CARDIO DIAGNOSTICS HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,120 (+3,02 %) liegt der Kurs bei 4,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARDIO DIAGNOSTICS HOLDINGS INC finden Sie auf Wallstreet Online.